

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/00, 35/14	A1	(11) International Publication Number: WO 96/09830 (43) International Publication Date: 4 April 1996 (04.04.96)
(21) International Application Number: PCT/US95/12125 (22) International Filing Date: 22 September 1995 (22.09.95) (30) Priority Data: 08/314,156 28 September 1994 (28.09.94) US 08/476,698 7 June 1995 (07.06.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/476,698 (CON) Filed on 7 June 1995 (07.06.95) (71) Applicant (for all designated States except US): THOMAS JEFFERSON UNIVERSITY [US/US]; 11th & Walnut Streets, Philadelphia, PA 19107 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SMITH, J., Bruce [US/US]; 430 South 5th Street, Philadelphia, PA 19146 (US). FORT, John, G. [US/US]; 708 South 2nd Street, Philadelphia, PA 19146 (US).		(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, Woodland Falls Corporate Park, Suite 201, 210 Lake Drive East, Cherry Hill, NJ 08002 (US). (81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOSITION AND METHOD FOR ALLOGENEIC MONONUCLEAR CELL IMMUNOTHERAPY (57) Abstract A method of treating autoimmune diseases is provided which involves administering an effective amount of allogeneic mononuclear cells or a molecule derived from these cells to an individual suffering from an autoimmune disease. Also provided are compositions for the treatment of autoimmune diseases.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**COMPOSITION AND METHOD FOR ALLOGENEIC
MONONUCLEAR CELL IMMUNOTHERAPY**

Background of the Invention

Tens of millions of people in the United States suffer
5 from rheumatoid arthritis (RA) or a related disease. While
arthritis results in significantly fewer deaths as compared to
cancer and cardiovascular diseases, there is no other group of
diseases that causes so much suffering in so many people for
such a prolonged period of time. Because of the tendency for
10 arthritis sufferers to become disabled and even permanently
crippled, this group of diseases is extremely important both
socially and economically. There is presently no satisfactory
cure for rheumatoid arthritis because its cause is unknown. In
addition, many of the therapeutic agents administered to
15 alleviate pain and inflammation associated with the disease,
such as disease-modifying antirheumatic drugs (DMARDs) and non-
steroidal anti-inflammatory agents (NSAIDs), produce
intolerable side effects.

The understanding of the RA disease process has been
20 considerably enhanced by the application of molecular
immunology techniques. It is now generally accepted that
rheumatoid arthritis represents a multifactorial disease with
environmental factors (infectious agents or toxins), genetic
susceptibility, and immune or autoimmune responses playing
25 inter-connected roles. After initiation of the disease
process, it is believed that activated T cells and their
products are responsible for the progressive destruction of

articular cartilage and sub-chondral bone that is characteristic of rheumatoid arthritis.

Advances in the understanding of the immunopathogenesis of rheumatoid arthritis have been coupled with immunologic strategies for treatment. Immunologic approaches to the treatment of rheumatoid arthritis are important and desirable given the potential toxicities associated with most remittive therapy in use today and the continued poor prognosis of rheumatoid arthritis despite aggressive drug treatment.

10 Monoclonal anti CD4 antibodies have been used in the treatment of rheumatoid arthritis (Reiter et al., *Arthritis Rheum.* **1991**, 34, 525-536; Horneff et al., *Arthritis Rheum.* **1991**, 34, 129-140; Herzog et al., *J. Autoimmunity* **1989**, 2, 627-642; Goldberg et al., *J. Autoimmunity* **1991**, 4, 617-630). In these studies, involving approximately 30 patients, objective and subjective improvement was noted in nearly all cases.

Another study employed chimeric monoclonal antibody to CD4 to treat 25 patients with refractory rheumatoid arthritis (Moreland et al., *Arthritis Rheum.* **1993**, 36, 307-318) and again, some beneficial effects were observed.

Immunotherapeutic approaches have also included leukapheresis, (Karsh et al., *Arthritis Rheum.* **1981**, 24, 867-873; Wallace et al., *Arthritis Rheum.* **1979**, 22, 703-710) thoracic duct drainage (Paulus et al., *Arthritis Rheum.* **1977**, 20, 1249-1262) and total node irradiation (Trentham et al., *N. Engl. J. Med.* **1981**, 305, 976-982). All of these modalities have resulted in varying degrees of improvement, but all also have obvious drawbacks.

Patients with rheumatoid arthritis have also been treated with one or more 5 day infusion courses with monoclonal anti-CD5 coupled to Ricin-A chain (Strand et al., *Arthritis Rheum.* **1993**, 36, 620-630). In this open-label trial, improvement rates were 50-68% at one month and 22-25% at 6 months (two clinical trials were included). All patients produced antibodies against the anti-CD5 conjugate and most experienced a transient decrease in CD3/CD5 positive T cells with recovery after 2-4 weeks.

Since cytokines also play important pathophysiologic roles in rheumatoid arthritis, research into therapeutics has also focused in this area. Tumor necrosis factor (TNF α) has received attention because it is consistently found in synovium
5 of patients suffering from rheumatoid arthritis. In addition, anti-human TNF was demonstrated to prevent the development of arthritis in a transgenic human TNF α mouse model. Using chimeric (mouse-human) antibodies to TNF α , twenty patients with active rheumatoid arthritis were treated (Elliott et al.,
10 *Arthritis Rheum.* 1993, 36, 1681-1690). Patients were given 20 mg/kg in divided doses weekly either over 2 or 4 weeks. They found overall improvement in the Ritchie Articular Index, joint count and C-reactive protein (CRP) levels, and reported no significant toxicity.

15 Immunization of patients having rheumatoid arthritis with autologous T cell lines established from cells obtained from RA synovial fluid (SF) and/or synovial tissue has also been shown to be of benefit in some patients (Kingsley and Verwilghen, *Clin. Exp. Rheumatol.* 1993, 11, S63-S64; Lohse et al., *J.*
20 *Autoimmunity* 1993, 1, 121-130; vanLaar et al., *J. Autoimmunity* 1993, 6, 159-167).

Regarding treatment of humans with allogeneic mononuclear cells (MNC), patients receiving living-related renal transplants have been transfused with allogeneic blood in an
25 attempt to limit the immune response. Similar therapies employing MNC have been applied in recurrent pregnancy loss since about 1981 based on the notion that the fetus represents an allogeneic "graft" and that women who have no demonstrable known cause for recurrent spontaneous abortion (RSA) are likely
30 to be immunologically rejecting their fetuses. Since 1985, the inventor has immunized over 1500 women diagnosed as having RSA with MNC from their spouses. World-wide it is estimated that about 25,000 patients have received this treatment. No serious side effects from this treatment have been found.

35 Remission of rheumatoid arthritis occurs in about 70% of all pregnant women suffering from rheumatoid arthritis. Pregnancy induced remission was originally believed to be due

to increased levels of cortisol but, clearly, it is not entirely due to hormonal effects. It has been observed that during pregnancy, women with rheumatoid arthritis who experience remission carry fetuses that are more disparate than
5 similar to themselves with respect to class II alleles of the human leukocyte antigens HLA-DRB1, -DQA and -DQB (Nelson et al., *N. Eng. J. Med.* **1993**, 329, 466-471). The immunologic mechanism(s) underlying this effect is not known; however, hypotheses include induction of suppressor mechanisms or
10 displacement of arthritogenic peptides from maternal antigen presenting cells (APC) by fetal class II peptides thus subverting an arthritis-inducing immune response. Alternatively, maternal T cell recognition of specific allogeneic or fetal HLA-DR peptides may cause a switch from a
15 predominantly proinflammatory response to one that is protective or suppressive.

While rheumatoid arthritis remains the prototype disease that improves during pregnancy, Multiple Sclerosis (MS) an autoimmune disease that affects about 160,000 women of
20 child-bearing age in the U.S. (Davis and Maslow, *Obstet. Gynecol. Surv.* **1992**, 47, 290-296) and that exhibits immunopathogenetic features similar to RA may be modulated by pregnancy. Pregnant patients with MS have been shown in retrospective studies to experience fewer exacerbations than
25 non-pregnant historical controls and to have post-partum disease flares (Davis and Maslow, *Obstet. Gynecol. Surv.* **1992**, 47, 290-296; Abramsky, O., *Ann. Neurol.* **1994**, 36, S38-S41; Hutchinson, M., *J. Neurol. Neurosurg. Psychiatry*, **1993**, 56, 1043-1045). Prospective studies of MS patients have confirmed
30 the retrospective analyses (Bernardi et al., *Acta Neurol. Scand.* **1991**, 84, 403-406; Birk et al., *Arch. Neurol.* **1990**, 47, 738-742; Rouillet et al., *J. Neurol. Neurosurg. Psychiatry* **1993**, 56, 1062-1065; Sadovnik et al., *Arch. Neurol.* **1994**, 51, 1120-1124). Furthermore, brain lesions in MS demonstrated by
35 magnetic resonance have been shown to improve during pregnancy and return to the pre-pregnancy state in the postpartum period (van Walderveen et al., *Neurology* **1994**, 44, 327-329). Like RA,

MS has been treated with immunosuppressive drugs and more recent trials have included the use of monoclonal antibodies to T cell subsets, T cell receptors, cytokines, and adhesion molecules (Whitaker J.N., *Ann. Neurol.* **1994**, 36, S103-S107; 5 Utz and McFarland, *J. Neuropath. Exp. Neurol.* **1994**, 53, 351-358). Recent studies demonstrate that a synthetic CD4 peptide analog inhibits experimental allergic encephalomyelitis (EAE) in a mouse model (Jameson et al., *Nature* **1994**, 368, 744-746). Immunomodulation using both alpha- and 10 beta-interferon have undergone clinical trials (Durelli et al., *Neurology* **1994**, 44, 406-413; Connelly, J.F., *Ann. Pharmacother.* **1994**, 28, 610-616).

Spondyloarthropathies (HLA-B27 related diseases) are more common in males than in females. However, ankylosing 15 spondylitis (AS), psoriatic arthritis (PS), and Reiter syndrome (RS) can affect women in the child-bearing age. Approximately 20% of patients suffering from the connective tissue disorder ankylosing spondylitis also experience remission of symptoms during pregnancy (Ostensen and Husby, "Seronegative 20 spondylarthritis and ankylosing spondylitis: Biological effects and management", *Pregnancy, Autoimmunity and Connective Tissue Disorders*, edited by Scott, J.S. and Bird, H.A., Oxford Univ. Press, Oxford, New York, Tokyo, 1990, p. 163-184). In addition, while a systematic study of pregnancy effects on 25 Psoriatic arthritis (PA) has not been reported, it is of interest that one of the pregnancy induced remission patients initially described by Hench in *Mayo Clin. Proc.* **1938**, 13, 161-167 had PA.

In addition, the organ-specific autoimmune disease, 30 Myasthenia gravis (MG), has been shown to have a variable response during pregnancy with about 30% of patients experiencing remission and 40% experiencing exacerbation (Varner, M.W., *Semin. Perinatol.* **1991**, 15, 238-250; Plauche, W.C., *Clin. Obstet. Gynecol.* **1983**, 26, 592-604).

35 The known phenomenon of pregnancy-induced remission and post partum exacerbation of rheumatoid arthritis (Persellin, RH, *Bull. Rheum. Dis.* **1976**, 77, 922-927) led to the use of

gamma globulin eluted from placentas in the treatment of rheumatoid arthritis. In one study, 11 patients were treated with placenta-eluted gamma globulin and improvement was noted in seven of these patients (Sany et al., *Arthritis Rheum.* 1982, 5 25, 17-24). High dose intravenous immunoglobulin (IVGG) has also been shown to be effective in modulating the course of rheumatoid arthritis (Tumiati et al., *Arthritis Rheum.* 1992, 35, 1126-1133). Ten patients with active, severe rheumatoid arthritis were treated with 6 monthly infusions. All patients 10 showed improvement; however, all patients also relapsed within weeks of the last infusion.

It has now been found that treatment of patients with active rheumatoid arthritis by immunization with allogeneic MNC can result in amelioration of symptoms and improvement in 15 disease activity indices. This treatment approach was taken in order to determine if the beneficial effects of pregnancy on these autoimmune diseases could be duplicated in non-pregnant patients. Treatment with allogeneic MNC can also be used in the treatment of a number of autoimmune disease, including, but 20 not limited to, Multiple Sclerosis, Spondyloarthropathies, and Myasthenia Gravis.

Summary of the Invention

An object of the present invention is to provide a method of treating autoimmune diseases which comprises administering 25 an effective amount of allogeneic mononuclear cells or molecules derived from these cells to an individual suffering from an autoimmune disease.

Another object of the present invention is to provide a composition for the treatment of autoimmune diseases comprising 30 purified allogeneic white blood cells or molecules derived from these cells.

Detailed Description of the Invention

Administration of an effective amount of allogeneic white blood cells or molecules derived from these cells can be used 35 to treat patients suffering from a number of different

autoimmune diseases. Examples of autoimmune diseases which can be treated by administration of these cells include, but are not limited to, rheumatoid arthritis, Multiple Sclerosis, Spondyloarthropathies, and Myasthenia Gravis. This treatment
5 can also be used as an adjunct to immunosuppressive drug treatment of organ graft recipients.

By "effective amount" it is meant a concentration of allogeneic mononuclear cells or molecules derived from these cells which, when administered to a patient suffering from an
10 autoimmune disease, produce a beneficial effect. For example, in patients suffering from rheumatoid arthritis, approximately 80 to 100 million cells administered in a standard buffered salt solution (Lactated Ringers solution) at 6-8 week intervals has been found to be an effective amount, alleviating patient
15 suffering.

Allogeneic MNC has been administered to 10 female patients with active rheumatoid arthritis. In each instance, MNC were obtained from the patient's spouse or an individual chosen by the patient. In this first trial, patients received
20 a series of at least 3 injections of approximately 10^8 MNC at 6 week intervals. No adverse effects were noted in any of the patients. Clear improvement in at least 2 of the parameters measured occurred in 7 of 10 patients. Table 1 shows results of Arthritis Impact Measurement Scales (AIMS) scores, which
25 provides a numerical means of following disease activity, physician global assessments, patient assessment of pain, swollen joint counts, and erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) determination in a number of patients entered.

TABLE 1

**Measure of Disease Activity in Patients
in the Preliminary Trial of Allogeneic
Mononuclear Cell Immunization for Rheumatoid Arthritis**

5

10

Patient	MNC Treatment	No. Cells given (x10 ⁶)	ESR or CRP	Physician Global Assess.	Patient Assess. of Pain	AIMS score	Swollen Joint Count
S.M.	Immuniz. #1	227	50 mm/hr	59	67	37.36	11
	Immuniz. #2	180	39	40	68	44.15	8
	Immuniz. #3	95	28	18	22	20.58	4
R.E.	Immuniz. #1	78	2.49 mg/dl	88	81	55.35	12
	Immuniz. #2	NR**	5.43	53	90	59.12	10
	Immuniz. #3	NR	2.53	47	45	45.87	8
J.B.	Immuniz. #1	97	50 mm/hr	43	25	53.06	8
	Immuniz. #2	55	66	27	16	37.38	11
	Immuniz. #3	150	47	16	30	36.09	4
L.C.	Immuniz. #1	175	34 mm/hr	51	42	41.60	12
	Immuniz. #2	165	NA	21	10	34.90	12
	Immuniz. #3	80	21	23	17	27.94	6
R.H.	Immuniz. #1	180	10 mm/hr	35	36	30.52	14
	Immuniz. #2	105	15	20	2	21.57	4
	Immuniz. #3	150	31	25	52	32.86	12
W.V.	Immuniz. #1	75	8 mm/hr	58	78	65.71	8
	Immuniz. #2	44	9	62	85	NA	7
	Immuniz. #3	120	6	34	78	73.21	8
B.C.	Immuniz. #1	113	43 mm/hr	45	72	ND	4

Patient	MNC Treatment	No. Cells given (x10 ⁶)	ESR or CRP	Physician Global Assess.	Patient Assess. of Pain	AIMS score	Swollen Joint Count
	Immuniz. #2	98	42	45	74	33.17	3
	Immuniz. #3	62	61	30	90	49.87	3
L.M.	Immuniz. #1	146	4.75 mg/dl	37	45	35.45	6
	Immuniz. #2	66	3.84	35	51	41.85	5
	Immuniz. #3	68	N.D.	45	59	43.37	3
M.O.	Immuniz. #1	75	26 mm/hr	75	81	50.90	18
	Immuniz. #2	37	20	52	65	43.80	6
	Immuniz. #3	99	22	60	61	48.44	16
M.R.	Immuniz. #1	84	65 mm/hr	35	63	34.61	15
	Immuniz. #2	93	84	41	64	41.82	5
	Immuniz. #3	140	48	37	51	32.17	3

In Table 1, ESR (erythrocyte sedimentation rate) is measured in mm/hr. CRP (C-reactive protein) is measured in mg/dl. ND means "not measured".

A summary of clinical disease activity assessments on the ten patients who have completed a series of three MNC treatments at 6 week intervals is provided in Table 2. Each separate analysis revealed statistically significant improvement at 95% confidence (paired Student's test).

TABLE 2

Mean Values of Disease Activity Measurements
in Ten Patients Before and After Completing
Three MNC Immunizations for Rheumatoid Arthritis

	AIMS Score	Physician Global Assess.	Patient Assess. of Pain	Swollen Joint Count
Before	44.98	52.6	59.0	10.8
After	40.06	33.5	52.3	6.6
p Value	<.02	<.001	<.006	<.001

It may be that class II major histocompatibility (MHC) gene products are responsible for the beneficial effect in RA observed after MNC treatment, just as it is class II disparity between a mother and fetus that appears to induce pregnancy-associated remission of RA. The genes of the major histocompatibility complex direct the synthesis of proteins that can be found on the surfaces of most cells. These proteins are referred to as the human leukocyte antigens (HLA) or sometimes as "MHC determinants". HLA are molecules that determine individuality within a species, bind and present antigens to immunocompetent cells, and are targets of graft rejection by immune effector cells. Thus, HLA are both necessary for immune responses to occur in individuals and can be targets of immune responses. HLA can bind an individual's own proteins and present these to the immune system. In some individuals this may result in autoimmune disease. MHC genes also determine susceptibility to certain diseases, for example, rheumatoid arthritis. HLA are designated class I or class II, based on their structure. Class I HLA are comprised of a single transmembrane alpha chain associated with beta-2 macroglobulin (β -2m) and usually interact with CD8+ cytotoxic T cells. Class II HLA have both alpha and beta transmembrane heavy chains and interact with CD4+ T cells that mediate helper and inducer effects and delayed-type hypersensitivity which is the classical histopathology of RA. Class I HLA antigens are present on virtually all nucleated cells in the body and are highly expressed on cells of the immune system. Class II HLA antigens are restricted in their distribution and are found predominantly on certain cells of the immune system. Relevant to the present invention, T cells express only class I antigens while B lymphocytes and monocytes express both class I and II antigens. These types of cells can be isolated from each other by depleting one or the other groups of cells thereby providing two sets of cells for comparison in immunization procedures. MNC prepared from whole blood contain T cells, B cells and monocytes. Only T cells remain when MNC is treated with an antibody directed against class II HLA antigens. An example of

such an antibody is the monoclonal antibody known as L243. Only B cells and monocytes remain if MNC is treated with a monoclonal antibody that only reacts with T cells. Anti CD3 is one example of such an antibody.

5 Patients suffering from an autoimmune disease such as rheumatoid arthritis, Multiple Sclerosis, Spondyloarthropathies, Myasthenia Gravis may be treated with whole MNC populations (containing monocytes, B cells and T cells) or a sub-population of MNC. Either the population of B
10 cells plus monocytes (positive for both class I and class II HLA molecules or the population of T cells (positive for class I but not class II HLA) are believed to mediate the effects. There are several means by which these cells can be effectively separated from each other which are routine to those of skill
15 in the art including, but not limited to, magnetic cell sorting that employs a device and reagents manufactured by Immunicon Corp. (Reg) Huntington Valley, PA. In one embodiment, MNC are treated with formalin to increase antigenicity of the cells and negate the possibility of these cells causing graft vs. host
20 disease in an immunocompromised individual.

It is also believed that a beneficial effect can result from the treatment of patients suffering from an autoimmune disease with purified class I or class II molecules. Presentation of these molecules on the allogeneic cell surface
25 is not required. Thus, compositions comprising purified class I and/or class II HLA molecules from single, selected or pooled donor white blood cells; portions of class I and/or II molecules (attenuated molecules or peptides) fractionated from whole molecule preparations; and synthetically prepared
30 peptides or larger molecules based on the knowledge of amino acid sequence and structure studies of the class I or II molecules may be administered.

In a preferred embodiment, compositions of the present invention which contain molecules as described above are
35 presented to the patient with the patients own mononuclear cells. For example, cells of specifically identified donors or the patient's own cells which are obtained, treated with the

composition and reinjected into the patient, can be used. The composition can be attached to the patient's own mononuclear cells in a number of ways, including chemical attachment of the relevant product to the patient's cells, and attachment of the
5 relevant product to the cells. In a preferred embodiment monocytes are used, as these cells have the capability of binding the class I or class II molecules/peptides as one of their normal functions. The procedures required to produce compositions of the present invention are routine to an
10 individual skilled in the arts of immunology and molecular biology/chemistry.

Methods of identifying appropriate patient donor pairs which increase the probability of the alloimmunization treatment being effective in a selected patient have also been
15 developed. These methods are based upon the measurement of specific differences between histocompatibility genes or antigens expressed on the MNC of donors and patients or *in vitro* immune responses of patient T lymphocytes to donor MNC or MNC membrane extracts or by determining the presence of
20 antibodies directed against MNC membrane extracts either before immunization or following the first treatment.

Susceptibility to the development of RA has been suggested to be related to a sequence of DNA that is found as an allelic variant in the third hypervariable region of HLA DR4
25 beta chain (DRB1) (Nepom et al., *Arth. and Rheumatism* **1989**, 32:15-21; Weyand et al., *Ann. Int. Med.* **1992**, 117:801-806). These sequences, known as DRB1*0401, *0404 and *0408, have been identified using sequence specific oligonucleotide probes (SSOP) in DNA extracts of leukocytes from RA patients. The
30 allelic variants are believed to either encode an HLA class II peptide that binds an arthritogenic substance or to encode a self class II peptide that stimulate arthritogenic T cell clones. Since the beneficial effect of alloimmunization of RA patients and patients suffering from an autoimmune disease may
35 be based upon specific differences between DRB DNA of donors and patients, DNA based tissue typing using SSOP can provide an indicator as to who will and who will not respond to treatment.

For example, if donor and patient shared or had closely related DRB1*0401 sequences than a beneficial effect of immunization would not be expected, whereas if they were significantly different, alloimmunization would be expected to be more effective.

Patients can also be selected for immunotherapy or donor-patient pairs on the basis of a patient's lymphocyte responses to a panel of donor lymphocytes or to donor MNC membrane extracts. Patient MNC can be cultured with donor MNC or membrane extracts and the cell proliferation can be measured by conventional methods such as [³H]-thymidine incorporation or IL-2 production by responding cells. In addition, culture supernatants from the donor-patient MNC pairs can be tested for the presence of TH2-related cytokines such as IL-4, IL-10 and TGF β . These cytokines are primarily suppressive of delayed-type hypersensitivity reactions which represents the immunopathology found in RA joint tissues. Thus, appropriate donor patient-pairs can be selected by determining which donor stimulates the strongest production of TH2 cytokines by patient lymphocytes.

Patient sera can also be tested for the presence of antibody to pooled MNC extracts. Using an enzyme linked immunosorbent assay (ELISA) and Western blotting, IgG and IgM antibodies against MNC membrane extracts were detected. Pooled MNC from 10 or more donors were used for the preparation of membrane extracts in accordance with the procedure described by Goldberg et al., *Am. J. Reprod. Immunol.* 1995 33:21-30. The membrane extracts was then used as the target antigen in an ELISA and as the antigen source in a polyacrylamide gel electrophoresis (PAGE) followed by Western blotting using patient sera as a source of antibody. Results of binding in ELISA and of finding antibodies in sera, when correlated to beneficial alloimmunization outcomes can provide another means of patient selection.

The following examples are provided for illustrative purposes only and are not intended to limit the invention in any way.

EXAMPLES**Example 1: Patient profiles and disease assessment**

Ten patients were treated in the first trial. None of the patients were receiving concomitant treatment with disease modifying anti-rheumatic drugs (DMARDs), and only one was receiving a small dose of prednisone (<10 mg/day). If patients were taking DMARDs, this treatment was discontinued for 6 weeks prior to entry into the immunotherapy trial. Disease activity was assessed clinically by patient global assessment of pain, physician global assessment of disease activity, AIMS questionnaire and swollen joint counts. Laboratory assessment included hematologic profile with platelet counts, erythrocyte sedimentation rate (ESR) and/or C-reactive protein determination (CRP). These parameters were recorded prior to entry into the study and 6 weeks thereafter including 6 weeks after the last injection of MNC in 2 patients and 9 months after the last injection in one patient. The latter patient has had no recurrence of active rheumatoid arthritis, the other two patients had evidence of active rheumatoid arthritis 6 weeks after the last injections. One of those patients, JB, improved after immunotherapy was reinstituted.

Example 2: Isolation of MNC

In each instance MNC were obtained from the patient's spouse or an individual chosen by the patient. MNC donors were screened for liver enzyme abnormalities, hepatitis B and C, human immunodeficiency viruses 1 (HIV-1) and 2 (HIV-2) and human T lymphotropic virus 2 (HTLV-2). Blood (100-120 ml) was obtained from the donors by venipuncture. This amount of blood usually yields between 80 and 150 X 10⁶ MNC after ficol-hypaque centrifugation. After washing in Earle's balanced salt solution, MNC were resuspended in 4 ml lactated Ringer's solution. Two ml were injected intravenously (IV) and the remaining 2 ml in divided doses of 0.5 ml each subcutaneously (SQ), at 4-6 week intervals. Clear improvement in at least 2 of the parameters measured occurred in 7 of 10 patients.

Example 3: Treatment protocol in larger clinical trials

Patients are divided into two groups, each group receiving a series of six treatments by intravenous bolus injection or subcutaneous injection. The patients in each group will be randomly assigned to receive different types of MNC. The randomization assignment is accomplished by a computer program so that by chance alone a patient will receive either MNC that are all positive for only class I HLA antigens (T cells) or MNC that are all positive for both class I and class II HLA antigens (B cells and monocytes). Immunizations will be performed at 6 week intervals using $80-100 \times 10^6$ cells each time. Patients in whom a beneficial effect is seen after 6 injections, are treated on a continuing basis but with graduated (2 weeks) lengthening of the interval between injections in order to determine the maximum time period that can elapse between treatments.

In the alternative, patients can also be randomized to receive allogeneic cells or a placebo such as autologous cells, i.e., their own cells, or saline injections in a randomized, double-blind placebo controlled prospective trial.

Example 4: Criteria for assessing clinical outcome

Clinical outcomes are assessed using the American College of Rheumatology (ACR) core criteria for disease activity. Six of these criteria are applied prior to study entry and at 6 week intervals during and for up to 12 weeks after completion of the trial. The criteria include swollen joint count, AIMS score, physician global assessment of disease activity (10 cm analog scale), patient assessment of pain (10 cm analog scale) and acute phase reactant value (ESR and/or CRP).

Example 5: Collection of MNC

When donor screening tests are complete, donors are scheduled with the TJU Blood Donor Center for obtaining a "buffy coat". MNC ($300-500 \times 10^6$) are recovered from "buffy coats" by ficol hypaque centrifugation. For patients randomized to receive only class I positive cells, class II

positive cells are depleted using supernatants of the L243 anti HLA-DR hybridoma cell line which is well known in the art. Patients randomized to receive class I and II positive cells receive cells magnetically depleted of CD3+ MNC. Cells
5 prepared for immunization are labeled and stored in liquid nitrogen in 90% fetal calf serum (FCS)/10% dimethyl sulfoxide (DMSO) until used for patient treatment. Greater than 90% of cells frozen in this manner are recovered.

What is Claimed:

1. A method of treating an autoimmune disease comprising administering an effective amount of allogeneic mononuclear cells to an individual suffering from an autoimmune
5 disease.

2. The method of claim 1 wherein the autoimmune disease comprises rheumatoid arthritis, Multiple Sclerosis Spondyloarthropathies, or Myasthenia Gravis

3. The method of claim 1 wherein the cells comprise B
10 cells.

4. The method of claim 1 wherein the cells comprise monocytes.

5. The method of claim 1 wherein the cells comprise T cells.

15 6. The method of claim 1 wherein the cells are treated with formalin.

7. A method of treating an autoimmune disease comprising administering an effective amount of molecules derived from allogeneic mononuclear cells to an individual
20 suffering from an autoimmune disease.

8. The method of claim 7 wherein the autoimmune disease comprises rheumatoid arthritis, Multiple Sclerosis Spondyloarthropathies, or Myasthenia Gravis

9. The method of claim 7 wherein the molecules derived
25 from allogeneic mononuclear cells comprise purified class I or class II HLA molecules.

10. The method of claim 7 wherein the molecules derived from allogeneic mononuclear cells comprise attenuated molecules or peptides fractionated from whole molecule preparations of class I or class II HLA molecules.
- 5 11. A composition for treatment of an autoimmune disease comprising purified allogeneic mononuclear cells.
12. The composition of claim 11 wherein the autoimmune disease comprises rheumatoid arthritis, Multiple Sclerosis Spondyloarthropathies, or Myasthenia Gravis
- 10 13. The composition of claim 11 wherein the cells are B cells.
14. The composition of claim 11 wherein the cells are monocytes.
- 15 15. The composition of claim 11 wherein the cells are T cells.
16. The composition of claim 11 wherein the cells are treated with formalin.
17. A composition for treatment of an autoimmune disease comprising molecules derived from allogeneic mononuclear cells.
- 20 18. The composition of claim 17 wherein the autoimmune disease comprises rheumatoid arthritis, Multiple Sclerosis Spondyloarthropathies, or Myasthenia Gravis.
19. The composition of claim 17 wherein the molecules derived from allogeneic mononuclear cells comprise purified
- 25 class I or class II HLA molecules.
20. The composition of claim 17 wherein the molecules derived from allogeneic mononuclear cells comprise attenuated

molecules or peptides fractionated from whole molecule preparations of class I or class II HLA molecules.

21. A method of enhancing immunosuppression in organ graft recipients comprising administering purified allogeneic mononuclear cells as an adjunct to immunosuppressive drug treatment in organ graft recipients.

22. A method of identifying patient donor pairs having an increased probability of effective alloimmunization treatment in a selected patient comprising measuring differences between selected histocompatibility antigens expressed on the MNC of donors and patients.

23. A method of identifying patient donor pairs having an increased probability of effective alloimmunization treatment in a selected patient comprising measuring in vitro immune responses of patient lymphocytes to donor MNC or MNC membrane extracts.

24. A method of identifying patient donor pairs having an increased probability of effective alloimmunization treatment in a selected patient comprising determining the presence of antibodies directed against MNC membrane extracts either before immunization or following the first treatment.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/12125

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 35/00, 35/14

US CL : 424/93.71, 534

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.1, 93.7, 93.71, 520, 529, 534; 514/825, 2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, search terms: allogeneic, mononuclear, cell(s), autoimmune, disease(s), arthritis, sclerosis, gravis, spondyloarthropath(y)(ies)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 5,239,062 (BLATTNER ET AL.) 24 AUGUST 1993, column 37, lines 1-57.	1-5, 7-24
---		-----
Y		6

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 JANUARY 1996

Date of mailing of the international search report

24 JAN 1996

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MICHAEL A. WILLIAMSON

Telephone No. (703) 308-1235